RNA sequencing-based microRNA expression signature in esophageal squamous cell carcinoma: oncogenic targets by antitumor miR-143-5p and miR-143-3p regulation.
Aged
Aged, 80 and over
Antagomirs
/ genetics
Biomarkers, Tumor
/ genetics
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cell Transformation, Neoplastic
/ genetics
Esophageal Squamous Cell Carcinoma
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ genetics
High-Throughput Nucleotide Sequencing
Humans
Male
MicroRNAs
/ genetics
Middle Aged
Neoplasm Proteins
/ genetics
Transcriptome
/ genetics
Journal
Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
26
03
2020
accepted:
22
06
2020
revised:
16
06
2020
pubmed:
6
7
2020
medline:
29
5
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
Aberrantly expressed microRNAs (miRNAs) disrupt intracellular RNA networks and contribute to malignant transformation of cancer cells. Utilizing the latest RNA sequencing technology, we newly created the miRNA expression signature of esophageal squamous cell carcinoma (ESCC). A total of 47 miRNAs were downregulated in ESCC tissues, and these miRNAs were candidates for antitumor miRNAs in ESCC cells. Analysis of the signature revealed that several passenger strands of miRNAs were significantly downregulated in ESCC, e.g., miR-28-3p, miR-30a-3p, miR-30c-3p, miR-133a-3p, miR-139-3p, miR-143-5p, and miR-145-3p. Recent studies indicate that some passenger strands of miRNAs closely involved in cancer pathogenesis. In this study, we focused on both strands of pre-miR-143, and investigated their antitumor roles and target oncogenes in ESCC. Ectopic expression of miR-143-5p and miR-143-3p significantly attenuated malignant phenotypes (e.g., proliferation, migration, and invasive abilities) in ESCC cell lines. We revealed that six genes (HN1, HMGA2, NETO2, STMN1, TCF3, and MET) were putative targets of miR-143-5p regulation, and one gene (KRT80) was a putative target of miR-143-3p regulation in ESCC cells. Our ESCC miRNA signature and analysis strategy provided important insights into the molecular pathogenesis of ESCC.
Identifiants
pubmed: 32623445
doi: 10.1038/s10038-020-0795-x
pii: 10.1038/s10038-020-0795-x
doi:
Substances chimiques
Antagomirs
0
Biomarkers, Tumor
0
MIRN143 microRNA, human
0
MIRN145 microRNA, human
0
MicroRNAs
0
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019-1034Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18K09338
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19K09077
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18K16322
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18K08626
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 17H04285
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23:233–42.
doi: 10.2188/jea.JE20120162
pubmed: 23629646
Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.
doi: 10.1016/S0140-6736(12)60643-6
pubmed: 23374478
Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50:12–20.
pubmed: 31535225
doi: 10.1007/s00595-019-01878-7
Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg. 2018;2:253–65.
pubmed: 30003188
pmcid: 6036369
doi: 10.1002/ags3.12174
Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49:412–20.
pubmed: 30920626
doi: 10.1093/jjco/hyz034
Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs—an update. Nat Rev Clin Oncol. 2018;15:541–63.
pubmed: 29784926
doi: 10.1038/s41571-018-0035-x
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.
pubmed: 25027649
doi: 10.1038/nrm3838
Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20:21–37.
pubmed: 30108335
pmcid: 6546304
doi: 10.1038/s41580-018-0045-7
Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.
pubmed: 25998712
pmcid: 4859809
doi: 10.1038/nrc3932
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Disco. 2017;16:203–22.
doi: 10.1038/nrd.2016.246
Koshizuka K, Nohata N, Hanazawa T, Kikkawa N, Arai T, Okato A, et al. Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs. Oncotarget. 2017;8:30288–304.
pubmed: 28415821
pmcid: 5444743
doi: 10.18632/oncotarget.16327
Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, et al. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer. 2017;117:409–20.
pubmed: 28641312
pmcid: 5537499
doi: 10.1038/bjc.2017.191
Yonemori K, Seki N, Idichi T, Kurahara H, Osako Y, Koshizuka K, et al. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Oncotarget. 2017;8:70097–115.
pubmed: 29050264
pmcid: 5642539
doi: 10.18632/oncotarget.19591
Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, et al. Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: regulation of NCAPH by antitumor miR-199a/b-3p. Int J Urol. 2019;26:506–20.
pubmed: 30818424
doi: 10.1111/iju.13911
Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, et al. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis. Mol Oncol. 2020;14:426–46.
pubmed: 31755218
doi: 10.1002/1878-0261.12602
Mitra R, Adams CM, Jiang W, Greenawalt E, Eischen CM. Pan-cancer analysis reveals cooperativity of bothstrands of microRNA that regulate tumorigenesis and patient survival. Nat Commun. 2020;11:968.
pubmed: 32080184
pmcid: 7033124
doi: 10.1038/s41467-020-14713-2
Matsushita R, Yoshino H, Enokida H, Goto Y, Miyamoto K, Yonemori M, et al. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness. Oncotarget. 2016;7:28460–87.
pubmed: 27072587
pmcid: 5053739
doi: 10.18632/oncotarget.8668
Mataki H, Seki N, Mizuno K, Nohata N, Kamikawaji K, Kumamoto T, et al. Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. Oncotarget. 2016;7:72084–98.
pubmed: 27765924
pmcid: 5342147
doi: 10.18632/oncotarget.12290
Yamada Y, Koshizuka K, Hanazawa T, Kikkawa N, Okato A, Idichi T, et al. Passenger strand of miR-145-3p acts as a tumor-suppressor by targeting MYO1B in head and neck squamous cell carcinoma. Int J Oncol. 2018;52:166–78.
pubmed: 29115582
Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Arai T, et al. Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis. J Hum Genet. 2018;63:1015–28.
pubmed: 30082847
doi: 10.1038/s10038-018-0497-9
Shimonosono M, Idichi T, Seki N, Yamada Y, Arai T, Arigami T, et al. Molecular pathogenesis of esophageal squamous cell carcinoma: identification of the antitumor effects of miR1453p on gene regulation. Int J Oncol. 2019;54:673–88.
pubmed: 30535463
Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127:2804–14.
pubmed: 21351259
doi: 10.1002/ijc.25284
Osako Y, Seki N, Kita Y, Yonemori K, Koshizuka K, Kurozumi A, et al. Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol. 2016;49:2255–64.
pubmed: 27779648
pmcid: 5117997
doi: 10.3892/ijo.2016.3745
Osako Y, Seki N, Koshizuka K, Okato A, Idichi T, Arai T, et al. Regulation of SPOCK1 by dual strands of pre-miR-150 inhibit cancer cell migration and invasion in esophageal squamous cell carcinoma. J Hum Genet. 2017;62:935–44.
pubmed: 28659612
doi: 10.1038/jhg.2017.69
Ni Y, Meng L, Wang L, Dong W, Shen H, Wang G, et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene. 2013;517:197–204.
pubmed: 23276710
doi: 10.1016/j.gene.2012.12.031
Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, et al. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS ONE. 2012;7:e33987.
pubmed: 22457808
pmcid: 3311581
doi: 10.1371/journal.pone.0033987
Zeinali T, Mansoori B, Mohammadi A, Baradaran B. Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother. 2019;109:195–207.
pubmed: 30396077
doi: 10.1016/j.biopha.2018.10.037
Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res. 2019;11:969–79.
pubmed: 30774425
pmcid: 6349084
doi: 10.2147/CMAR.S191696
Xu WX, Liu Z, Deng F, Wang DD, Li XW, Tian T, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res. 2019;11:6739–53.
pubmed: 31814885
pmcid: 6895535
Hu M, Zhang Q, Tian XH, Wang JL, Niu YX, Li G. lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis. Mol Carcinog. 2019;58:2207–17.
pubmed: 31544294
doi: 10.1002/mc.23109
Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 2009;106:3207–12.
pubmed: 19202062
doi: 10.1073/pnas.0808042106
pmcid: 2651330
Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, et al. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol. 2013;19:7758–65.
pubmed: 24616567
pmcid: 3837276
doi: 10.3748/wjg.v19.i43.7758
He M, Zhan M, Chen W, Xu S, Long M, Shen H, et al. MiR-143-5p deficiency triggers EMT and metastasis by targeting HIF-1alpha in gallbladder cancer. Cell Physiol Biochem. 2017;42:2078–92.
pubmed: 28803245
doi: 10.1159/000479903
Sanada H, Seki N, Mizuno K, Misono S, Uchida A, Yamada Y, et al. Involvement of dual strands of miR-143 (miR-143-5p and miR-143-3p) and their target oncogenes in the molecular pathogenesis of lung adenocarcinoma. Int J Mol Sci. 2019;20:4482.
pmcid: 6770575
doi: 10.3390/ijms20184482
Talebi A, Masoodi M, Mirzaei A, Mehrad-Majd H, Azizpour M, Akbari A. Biological and clinical relevance of metastasis-associated long noncoding RNAs in esophageal squamous cell carcinoma: a systematic review. J Cell Physiol. 2020;235:848–68.
pubmed: 31310341
doi: 10.1002/jcp.29083
Sugihara H, Ishimoto T, Miyake K, Izumi D, Baba Y, Yoshida N, et al. Noncoding RNA expression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma. Int J Mol Sci. 2015;16:27824–34.
pubmed: 26610479
pmcid: 4661918
doi: 10.3390/ijms161126060
Wu F, Gao H, Liu K, Gao B, Ren H, Li Z, et al. The lncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1alpha axis. Onco Targets Ther. 2019;12:657–67.
pubmed: 30705594
pmcid: 6343511
doi: 10.2147/OTT.S175521
Liu C, Wang JO, Zhou WY, Chang XY, Zhang MM, Zhang Y, et al. Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p. Mol Cell Endocrinol. 2019;493:110424.
pubmed: 30991076
doi: 10.1016/j.mce.2019.04.004
Jin X, Chen X, Hu Y, Ying F, Zou R, Lin F, et al. LncRNA-TCONS_00026907 is involved in the progression and prognosis of cervical cancer through inhibiting miR-143-5p. Cancer Med. 2017;6:1409–23.
pubmed: 28544557
pmcid: 5463062
doi: 10.1002/cam4.1084
Yang C, Shen S, Zheng X, Ye K, Sun Y, Lu Y, et al. Long noncoding RNA HAGLR acts as a microRNA-143-5p sponge to regulate epithelial-mesenchymal transition and metastatic potential in esophageal cancer by regulating LAMP3. FASEB J. 2019;33:10490–504.
pubmed: 31311326
doi: 10.1096/fj.201802543RR
Young AR, Narita M. Oncogenic HMGA2: short or small? Genes Dev. 2007;21:1005–9.
pubmed: 17473167
doi: 10.1101/gad.1554707
Hammond SM, Sharpless NE. HMGA2, microRNAs, and stem cell aging. Cell. 2008;135:1013–6.
pubmed: 19070572
pmcid: 3725266
doi: 10.1016/j.cell.2008.11.026
Pfannkuche K, Summer H, Li O, Hescheler J, Droge P. The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev Rep. 2009;5:224–30.
pubmed: 19551524
doi: 10.1007/s12015-009-9078-9
Fedele M, Palmieri D, Fusco A. HMGA2: a pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol. 2010;326:19–24.
pubmed: 20347930
doi: 10.1016/j.mce.2010.03.019
Zhang S, Mo Q, Wang X. Oncological role of HMGA2 (Review). Int J Oncol. 2019;55:775–88.
pubmed: 31432151
Palumbo A Jr, Da Costa NM, Esposito F, De Martino M, D'Angelo D, de Sousa VP, et al. HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma. Oncotarget. 2016;7:25872–84.
pubmed: 27027341
pmcid: 5041951
doi: 10.18632/oncotarget.8288
Palumbo Junior A, Da Costa NM, Esposito F, Fusco A, Pinto LF. High mobility group A proteins in esophageal carcinomas. Cell Cycle. 2016;15:2410–3.
pubmed: 27484584
pmcid: 5026802
doi: 10.1080/15384101.2016.1215388
Wei R, Shang Z, Leng J, Cui L. Increased expression of high-mobility group A2: a novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma. J Cancer Res Ther. 2016;12:1291–97.
pubmed: 28169242
doi: 10.4103/0973-1482.148726
Li C, Liu X, Liu Y, Liu X, Wang R, Liao J, et al. Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway. Cell Death Dis. 2018;9:1009.
pubmed: 30262880
pmcid: 6160410
doi: 10.1038/s41419-018-1030-y